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Results: For the entire group median follow-up and overall 
survival (OS) were: 17.7 months (mo) (IQR: 10.3-27.9) and 
19.1 mo (95% CI 13.9-24.3). Median tBED for entire group was 
45.8 Gy (IQR 40.5-49) tBED in SD and ED group were 42.2 (IQR 
37.4-45.2) and 48.9 Gy (IQR 45.7-49.7) Univariate analysis by 
groups: Actuarial median OS: SD vs. ED was: 17 mo (95% CI 
13.6-20.3) vs. 22.3 mo (95% CI 9.6-35) p = 0.18. Actuarial 
median DFS SD vs. ED was: 8.3 (95% IC 7.2 – 9.3) vs. 12.8 mo 
(95% IC 3 – 22.7) p = 0.009. Actuarial median TPFS (mo) SD vs. 
ED was: 8.4 (95% CI 7.2-9.5) vs. 21.8 (95% CI 13.2-30.5) p = 
0.003.  
On multivariate analysis significant predictors for OS, DFS and 
TPFS are depicted on table: radiotherapy dose was found not 
to be a significant factor.  
 
 
 
Conclusion: On univariate analysis, but not on multivariate, 
ED associated statistically significant better DFS and TPFS 
and non-statistically significant better OS, even when 
adjusted to overall treatment time. Due to treatment time 
delays SD group received a suboptimal dose of radiotherapy 
and ED group received a tBED which virtually match nominal 
60 Gy. Our data in agreement with those resulting from 
randomized trials strongly support that 60 Gy @2 Gy with 
stringent control of time delays is the gold standard in the 
radiotherapy for NSCLC. 
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Purpose or Objective: Radiotherapy with or without 
chemotherapy is commonly used for isolated loco-regional 
recurrence of non-small cell lung cancer (NSCLC) after initial 
surgery. This study was undertaken to evaluate the outcomes 
and complications of curative radiotherapy for locoregionally 
recurrent NSCLC. 
 
Material and Methods: Medical records of 57 patients who 
received curative radiotherapy for locoregionally recurrent 
NSCLC without distant metastasis after surgery from 2004 to 
2014 were retrospectively reviewed. At the time of 
recurrence, the median age was 67 years (range 34-81 years), 
and most patients (84.2%) have good ECOG performance 
status. All patients initially received a curative intent 
operation, and the median disease-free interval was 14 
months. For locoregionally recurrent lung cancer, forty-two 
patients were treated with concurrent chemoradiotherapy 
(CCRT), and 15 patients with radiotherapy alone. Radiation 
dose ranged from 45 Gy to 70 Gy (median 66 Gy) by a three-
dimensional conformal technique. Lung function change after 
radiotherapy was evaluated by comparing pulmonary function 
tests before and after radiotherapy. 
 
Results: Median follow-up after recurrence was 20 months. 
Six patients showed a complete response, and 39 patients 
showed a partial response. The median survival was 30 
months. Two-year locoregional recurrence-free survival 
(LRFS), distant metastasis-free survival (DMFS), disease-free 
survival (DFS) and overall survival (OS) rate were 46.1%, 
37.2%, 31.9%, and 65.1%, respectively. Eleven patients 
showed disease progression within the radiation field after 
radiotherapy. Pulmonary function decreased meaningfully 
after radiotherapy, and radiation pneumonitis of any grade 
was seen in 19 patients. In the multivariate analysis, age 
under 70 years was associated with good OS (p=0.047); 
concurrent chemoradiotherapy with good OS (p=0.014), and 
DFS (p=0.003); and single-station recurrence with good OS 
(p=0.01), DFS (p=0.022), and LRFS (p=0.01). 
 
Conclusion: Patients who have locoregionally recurrent 
NSCLC showed favorable survival outcomes with salvage 
radiotherapy. However, lung function should be carefully 
evaluated before and after radiotherapy. Young age, single 
site recurrence, and the use of CCRT were good prognostic 
factors of overall survival. In patients with good prognostic 
factors and suitable for curative radiotherapy, CCRT could be 
considered to improve treatment outcomes. 
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Purpose or Objective: Precise delineation of primary lung 
cancer mass and involved mediastinal LN is very important 
requirement in order to improve radiotherapy outcome and 
minimize treatment toxicity. Diffusion weighted MRI (DW-
MRI) is a recently introduced functional imaging modality, 
having higher sensitivity and specificity than CT to 
differentiate lung cancer from post-obstructive lobar collapse 
. And also able to pinpoint lymph nodes with and without 
metastasis. The apparent diffusion coefficient (ADC) is the 
quantitative parameter of DW-MRI with cut off value 1.4 x 
103 mm2/s which can be used as a good tool to contour 
Target volumes in lung cancer. 
the aim is to study the feasibility of using the images of DW-
MRI and data of ADC map for radiotherapy contouring 
purposes 
 
Material and Methods: Twenty cases of newly diagnosed lung 
cancer patients underwent CT chest with contrast and 
respiratory gatted DW-MRI with b value of 0, 500, 1000s/mms 
. Both studies were obtained in the same position, respiratory 
phase and slice thickness (5mm) in order to allow proper 
image fusion. For each patient, we’ve delineated GTV for 
primary lung mass and GTV- LN for involved mediastinal LN 
on both CT scan (guided by size) and DW-MRI (guided by T2W 
and the ADC map ) together with delineation of the nearby 
risk structures. Auto margins were taken for the CTV and the 
PTV. The impact of using MRI on stage and different treated 
volumes was assessed and compared. 
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Results: The main result was the reduction in primary and 
nodal volumes due to better definition of lung mass and 
nearby lung Collapse , the latter could be easily defined in 14 
cases on the DW-MRI vs. 7 cases only by CT scans (P=0.016). 
Median GTV total (sum of 1ry and nodal GTV), on MRI 
Diffusion compared to that on the CT scan was 354 and 386 
cm3 respectively (P= 0.009). In 15 cases, a mean decrease in 
the GTV total of 34% ±56% (median, 9%; range, 0.2- 32.5%) by 
using DW-MRI. only in three other cases a mean increase in 
the GTV total of 12.7% ±14.9% (median, 9.7%; range, 0.4- 
221%). was found. The median PTVs on the CT scans vs. the 
MRI Diffusion were 1623 (range, 493–2965 cm3) & 1419 
(range, 542–3158 cm3) respectively which was statistically 
non significant (P= 0.391).  
 
Conclusion: This pilot prospective study concluded that DW-
MRI as a functional image can aid in proper definition and 
delineation of the target volumes after fusion of DWI and the 
CT images . GTV Total decreased in most cases due to 
exclusion of collapse, consolidation, reactionary and 
inflammatory LN, however GTV total was increased in 3/20 
patients due to better nodal detection and better 
visualization of borders adjacent to the mediastinum and 
chest wall. DW MRI could be a future good tool for proper 
staging and guidance of radiotherapy in NSCLC cases 
indicated for chemo/radiation. 
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Purpose or Objective: Purpose: The aim of this work was to 
compare the patterns of NSCLC relapses after combined 
modality therapy with postoperative hypofractionated and 
conventionally fractionated radiotherapy and after sugery 
 
Material and Methods: Material/methods. We treated 528 
patients between January 1990 and January 2014 (men – 445, 
women – 83) aged 27-78 years (median age 59) with 
morphologically proven NSCLC (adenocarcinoma - 161, 
squamous cell cancer– 289, other types – 70 patients); stage 
I-126, stage II - 117, III - 111. All patients were operated: 
pnevmonectomy -180, lobe/belobectomy – 304, 
segmentectomy – 30, wedge resection -11. 227 patients 
received neoadjuvant or adjuvant platinum-based 
chemotherapy. Three groups were retrospectively analyzed: 
group I - 174 patients without postoperative radiotherapy 
(PORT), group II - 180 patients with postoperative 
hypofractionated radiotherapy with daily dose 3Gy up to the 
total dose 36Gy-39Gy (EQD2=43-47Gy, α/β=3) and group III - 
174 patients with postoperative radiotherapy with daily dose 
2Gy up to the total dose 44Gy. Bronchial stump, involved 
regional lymphatic nodes and uninvolved groups (2R, 2L, 3a, 
3p, 4R, 4L, 5, 6, 7 according to IASLC classification) were 
included in the CTV. The groups were comparable in the 
following parameters: age, ECOG status, stage, T- and N - 
classification and the proportion of the patients treated with 
chemotherapy. The duration of the follow-up was 0,33-16,0 
years, median - 2,25 years. The relapses were classified as 
local (in bronchial stump), regional, or distant. In the cases 
of mixt relapses (local ± regional ±distant) they were 
included in each category. 
 
Results: Results. 263(49,8%) patients relapsed: 231 (43,8%) 
had distant metastases, local relapse – 51 (9,7%), regional 
relapse – 54 (10,2%). The pattern of the relapses in each 
group is presented in the table. 
 
 
 
Conclusion: Conclusion. Hypofractionated postoperative 
radiotherapy (daily dose 3Gy, total dose 36-39Gy) 
significantly decrease the probability of local and regional 
relapse in NSCLC patients as well as the total number of the 
relapses without any effect with regard to distant 
metastases. Hypofractionated PORT is equally effective as 
conventional PORT (daily dose 2Gy, total dose 44Gy) with 
regard to locoregional control but has the clear logistical 
advantage. 
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Purpose or Objective: Increasing the radiotherapy dose can 
result in improved local control for non-small-cell lung cancer 
(NSCLC) and can thereby improve survival. This can be 
compromised by accelerated repopulation of tumour cells 
during radiotherapy. Accelerated hypofractionated 
radiotherapy (AHRT) can expose tumors to a high dose of 
radiation in a short period of time. We have employed this 
approach in two groups of NSCLC: 1) early stage NSCLC 
patients who cannot tolerate the SABR treatment process (for 
example, extended periods in the treatment position) or who 
cannot travel to a centre with SABR; and 2) stage III NSCLC 
unfit for concurrent chemotheraphy.  
This study was performed to evaluate the feasibility of 
utilizing AHRT for these patients. 
 
Material and Methods: 76 patients (46 stage I-II and 30 local 
advanced NSCLC) were included. All patients had FDG-PET 
scan. Only the primary tumour and the positive mediastinal 
areas on the pre-treatmement FDG-PET scan were irradiated. 
Mean age was 77.9 ± 7.9 years. The performance status (PS) 
was > 2 in 50% of cases. The radiotherapy was delivered in 
2.75 Gy fractions, once daily to a total dose of 66 Gy (BED10: 
84 Gy). Sequential chemotheraphy (mainly platinum and 
vinorelbine) was administered in 95% of stage III patients. 
Acute/late toxicity was evaluated using the RTOG criteria. 
 
Results: After a mean follow-up of 2 years, the median 
overall survival (OS) and cause specific survival (CSS) were 23 
and 54 months, respectively. On multivariate Cox regression 
analysis, PS >2 was an independent risk factor for OS 
(p<0.0001) and CSS (p<0.0001). The major acute adverse 
reactions were grade 2 dermitis (18%), grade 2 esophagitis 
(10%) and grade 1 pneumonitis (26%). There were 34 patients 
with grade 1 late pneumonitis. 
